Online citations, reference lists, and bibliographies.
← Back to Search

Idiopathic Thrombocytopenic Purpura In Egyptian Children.

A. Khalifa, K. A. Tolba, Mohsen Saleh Elalfy, M. Gadallah, F. Ibrahim
Published 1993 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
350 patients with idiopathic thrombocytopenic purpura (ITP) aged 2/12-15 years (mean 6.3 +/- 2.7) were followed up during the period January 1st, 1975 to March 31, 1992. They constituted 40% of cases with hemorrhagic diathesis attending the Hematology/Oncology Clinic, Children's Hospital, Ain Shams University (relative frequency of 37.4/100.000 of the general Out-Patient Clinic in the same hospital). These patients presented with acute (71.4%), chronic (22.9%) and recurrent (5.7%) forms. The age of presentation was younger in acute ITP. In the recurrent form there was significant female predominance. Most cases of acute ITP (66%) presented in winter and spring, with a positive history of preceding viral illness in 50% in contrast to 10% in chronic form. Four chronic ITP cases developed lupus erythematosus; all were females > 9 years. As regards therapy, acute ITP cases with initial platelet count (PC) < 10 x 10(9)/l were randomized to receive either high-dose methyl prednisolone (HDMP) 10 mg/kg/day for 5 days i.v. (n = 10) or intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days (n = 10) or conventional-dose prednisone (CDP) 2 mg/kg/day 4 weeks p.o. (n = 10). A dramatic response was noticed in the first two groups. In chronic ITP, (n = 80) CDP induced complete response (CR) in 30% and partial response (PR) in 20%; 50% were nonresponders. Twenty-four refractory ITP with persistent PC < or = 20 x 10(9)/l received second-line therapy: vincristine 1.5 mg/m2/week i.v. 4 doses (n = 4) with no clinical or hematological improvement. IVIG 0.4 g/kg/day for 5 days (n = 8) with sustained CR only in 2 patients (25%) and PR in 2 patients (25%). Splenectomy was performed (n = 12) with CR in 50%; out of them, 2 patients had shown no improvement on prior IVIG therapy. In conclusion, ITP is a benign condition with no fatality reported, but it could run a chronic refractory course.



This paper is referenced by
10.1016/S2352-3026(16)30109-0
High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis.
Siraj Mithoowani (2016)
10.1053/j.seminhematol.2013.03.019
Three decades of experience in managing immune thrombocytopenia in children in Arab countries.
Mohsen Saleh Elalfy (2013)
Evaluation of Prognostic Factors in Newly Diagnosed Childhood Primary Immune Thrombocytopenia ( ITP ) : Two-Year Prospective Study at Al-Sadder Hospital , Missan Province
S. Al-Zuhairy (2013)
10.1002/ajh.22081
Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia
B. Fresneau (2011)
10.1177/1076029610379849
The Clinical Outcome of 260 Pediatric ITP Patients in One Center
S. Akbayram (2011)
10.1002/pbc.22346
Outcome of chronic idiopathic thrombocytopenic purpura in children
D. Bansal (2010)
10.5152/tjh.2010.21
Variant clinical courses in children with immune thrombocytopenic purpura: Sixteen year experience of a single medical center.
Işın Yaprak (2010)
10.1159/000262293
Intracranial Hemorrhage in Acute and Chronic Childhood Immune Thrombocytopenic Purpura over a Ten-Year Period: An Egyptian Multicenter Study
Mohsen Saleh Elalfy (2009)
10.1002/pbc.21569
Recurrent idiopathic thrombocytopenic purpura in childhood
Maria Vranou (2008)
Supporting Informed Decisions Polyclonal Intravenous Immunoglobulin in Patients with Immune Thrombocytopenic Purpura : Clinical Systematic
Stella Chen (2008)
10.1016/J.TMRV.2007.01.001
Guidelines on the use of intravenous immune globulin for hematologic conditions.
D. Anderson (2007)
Acute immune thrombocytopenic purpura in children.
A. Rehman (2007)
10.1002/pbc.20830
A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
Sarah H. O'Brien (2007)
10.1007/s00112-006-1350-3
Strategien zur Behandlung von Thrombozytopenien im Kindesalter
W. Ebell (2006)
10.1159/000089465
Randomized Trial of Anti-D Immunoglobulin versus Low-Dose Intravenous Immunoglobulin in the Treatment of Childhood Chronic Idiopathic Thrombocytopenic Purpura
Mohsen S El Alfy (2006)
10.1080/08880010600962143
RECURRENT IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN
S. Jayabose (2006)
10.1016/J.JPEDS.2005.04.032
Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials.
C. Beck (2005)
10.1159/000072409
5- to 16-Year Follow-Up following Splenectomy in Chronic Immune Thrombocytopenic Purpura in Children
Mohsen Saleh Elalfy (2003)
Should we do away with case reports
Van Der Meer Jw (2002)
10.3324/%X
Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica.
D. De Mattia (2000)
10.1111/j.1651-2227.1998.tb01240.x
Current management issues of childhood and adult immune thrombocytopenic purpura (ITP)
T. Kühne (1998)
10.1016/S0929-693X(97)83461-6
Purpura thrombopénique idiopathique chez 87 enfants: évolution à long terme
J. Choulot (1998)
10.1111/j.1600-0609.1998.tb01002.x
Intravenous immunoglobulin treatment in hematological diseases
A. Otten (1998)
10.1182/BLOOD.V88.1.3.BLOODJOURNAL8813
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
J. George (1996)
Semantic Scholar Logo Some data provided by SemanticScholar